IO Biotech, Inc.

Equities

IOBT

US4497781090

Biotechnology & Medical Research

Market Closed - Nasdaq Other stock markets 04:30:01 2024-04-26 pm EDT			5-day change	1st Jan Change
1.42 ^USD	-2.07%		-4.05%	-24.47%

Apr. 26	IO Biotech, Inc. Announces Resignation of Jack Nielsen as Member of the Board of Directors	CI
Apr. 15	IO Biotech Announces Marjan Shamsaei as Senior Vice President	CI

IO Biotech, Inc. Reports Earnings Results for the Fourth Quarter Ended December 31, 2023

March 05, 2024 at 04:47 pm EST

IO Biotech, Inc. reported earnings results for the fourth quarter ended December 31, 2023. For the fourth quarter, the company reported net loss was USD 26.18 million compared to USD 20.07 million a year ago. Basic loss per share from continuing operations was USD 0.4 compared to USD 0.7 a year ago.

Latest news about IO Biotech, Inc.

IO Biotech, Inc. Announces Resignation of Jack Nielsen as Member of the Board of Directors	Apr. 26	CI
IO Biotech Announces Marjan Shamsaei as Senior Vice President	Apr. 15	CI
IO Biotech, Inc. Presents New Data At Aacr 2024 Further Supporting Dual Mechanism of Action of Lead Cancer Vaccine, Io102-Io103	Apr. 09	CI
IO Biotech, Inc. Appoints Faiçal Miyara as Chief Business Officer	Apr. 05	CI
IO Biotech Announces Acceptance of Abstract to Be Presented at the 2024 American Association for Cancer Research Annual Meeting	Mar. 06	CI
IO Biotech, Inc. Reports Earnings Results for the Fourth Quarter Ended December 31, 2023	Mar. 05	CI
IO Biotech, Inc. Reports Earnings Results for the Full Year Ended December 31, 2023	Mar. 05	CI
IO Biotech Doses First Patient in Phase 2 Trial of Melanoma Treatment	Dec. 21	MT
IO Biotech Announces First Patient Dosed in Phase 2 Neoadjuvant/Adjuvant Solid Tumor Basket Trial	Dec. 21	CI
IO Biotech, Inc. Reports Earnings Results for the Third Quarter and Nine Months Ended September 30, 2023	Nov. 13	CI
IO Biotech Appoints Helen Collins, Md, to Its Board of Directors	Nov. 13	CI
IO Biotech Completes Enrollment in Pivotal Phase 3 Trial in Advanced Melanoma	Nov. 10	MT
IO Biotech Completes Enrollment of 380 Patients in Pivotal Phase 3 Trial in Advanced Melanoma	Nov. 10	CI
IO Biotech Says Non-Small Cell Lung Cancer Therapy Showed Partial Response in More Than Half of Evaluable Patients	23-10-23	MT
IO Biotech, Inc. Announces Encouraging Preliminary Data from a Phase 2 Trial Evaluating IO102-IO103 in Combination with Pembrolizumab for First-line Treatment of Patients with Non-small Cell Lung Cancer and Squamous Cell Carcinoma of the Head and Neck Presented at the European Society for Medical Oncology Congress	23-10-23	CI
Piper Sandler Starts IO Biotech at Overweight	23-09-28	MT
Transcript : IO Biotech, Inc. Presents at Morgan Stanley 21st Annual Global Healthcare Conference 2023, Sep-12-2023 04:15 PM	23-09-12
IO Biotech Reports 'Encouraging' Data from Phase 2 Trial of IO102-IO103, Keytruda Combination to Treat Lung Cancer	23-09-12	MT
Morgan Stanley Adjusts Price Target on IO Biotech to $7 From $11, Maintains Overweight Rating	23-08-15	MT
IO Biotech, Inc. Reports Earnings Results for the Second Quarter and Six Months Ended June 30, 2023	23-08-11	CI
IO Biotech, Inc. Appoints Heidi Hunter to Its Board of Directors	23-08-11	CI
IO Biotech Launching $75 Million Private Stock Placement; Shares Rise	23-08-07	MT
IO Biotech, Inc. announced that it expects to receive $75.057935 million in funding from a group of investors	23-08-06	CI
IO Biotech Announces First Patient Dosed in Investigator-Initiated Phase 1 Trial At University of California Davis Comprehensive Cancer Center	23-07-28	CI
IO Biotech Names Dr. Qasim Ahmad as Chief Medical Officer	23-07-18	MT

Chart IO Biotech, Inc.

Duration

Period

More charts

Company Profile

IO Biotech Inc is a clinical-stage biopharmaceutical company developing immune-modulating cancer therapies based on T-win technology platform. The Companyâs product candidates are designed to induce the immune system to simultaneously target and disrupt multiple pathways that regulate tumor-induced immunosuppression. IO Biotechâs lead product candidate, IO102-IO103, is designed to target the immunosuppressive mechanisms mediated by key immunosuppressive proteins such as IDO and PD-L1. The Company develops a pipeline of product candidates that leverage its T-win technology platform to address targets within the TME. The Company is spin-off of National Cancer for Center Immune Therapy at Herlev University Hospital in Denmark.

Sector

Biotechnology & Medical Research

Calendar

2024-05-12 - Q1 2024 Earnings Release (Projected)

More about the company

Income Statement Evolution

More financial data

Analysts' Consensus

Sell

Buy

Mean consensus

BUY

Number of Analysts

Last Close Price

1.42 USD

Average target price

8.75 USD

Spread / Average Target

+516.20%

Consensus

EPS Revisions

Estimates Revisions

Quarterly earnings - Rate of surprise

Company calendar

Sector Other Biotechnology & Medical Research

	1st Jan change	Capi.
IO BIOTECH, INC.	-24.47%	93.55M
IQVIA HOLDINGS INC.	+1.51%	42.75B
MODERNA, INC.	+8.57%	41.34B
LONZA GROUP AG	+49.22%	41.61B
CELLTRION, INC.	-12.36%	26.59B
ICON PUBLIC LIMITED COMPANY	+8.92%	25.49B
ALNYLAM PHARMACEUTICALS, INC.	-25.13%	18.12B
MEDPACE HOLDINGS, INC.	+29.17%	12.24B
CHARLES RIVER LABORATORIES INTERNATIONAL, INC.	-3.12%	11.76B
UNITED THERAPEUTICS CORPORATION	+6.35%	11B

Other Biotechnology & Medical Research